MedPath

Prospective Registration of Severe Pneumocystis Jiroveci Pneumonia Requiring ICU Admission

Conditions
Intensive Care Unit
Pneumocystis Jiroveci Pneumonia
Registration Number
NCT03201497
Lead Sponsor
Peking Union Medical College Hospital
Brief Summary

the investigators aim to set up a multicenter registry study for severe PJP requiring ICU admission. The purpose of this study is

1. to establish a prospective severe PJP registry about clinical characteristics, laboratory and radiographic findings, critical care management and outcomes.

2. to explore the predictive factors associated with outcomes ;

3. to compare the difference between PJP patients with HIV and without HIV infection.

Detailed Description

Pneumocystis jiroveci pneumonia (PJP) is a common opportunistic infection in immunocompromised patients. Although the mortality of patients with mild to moderate PJP has declined substantially, the reported outcomes of severe PJP requiring ICU admission, especially with mechanical ventilation are grave. The data on this group of patients is very limited and mainly comes from retrospective studies.

the investigators aim to set up a multicenter registry study for patient with severe PJP requiring ICU admission to provide comprehensive descriptive data on diagnosis, clinical course, critical care management and outcomes in a large cohort.

All patients with PJP admitted to the participating ICU during a two-year period will be enrolled. The CRF will be made available to the participating sites as a printable paper-based CRF.

The following individual patient data for study participants will be collected:

* General demographic information

* Presence of risk factors for PJP and comorbid condition

* use of prophylactic SMZ/TMP, immunosuppressive medications prior to ICU admission

* Information about PJP and co-infection diagnosis

* vital signs, laboratory(blood serum and BALF sample) and radiologic data at ICU admission and during ICU stay

* organ failures and severity of the disease at admission, new onset of organ failures during ICU stay

* Medications for PJP, time course and modalities and settings for respiratory support

* ICU, 28-day mortality, hospital, 90-day mortality

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
300
Inclusion Criteria
  • diagnosis with PJP, confirmed by PCR or methenamine silver stain of sample from BALF, aspirate or sputum;
  • ICU admission due to PJP-related respiratory failure
Exclusion Criteria
  • NO

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
28-day ICU mortalityDay 28

28 days mortality after ICU admission

Secondary Outcome Measures
NameTimeMethod
ICU length of stayDay 90

ICU length of stay at ICU discharge

occurrence of pneumothorax or pneumomediastinumday 28

pneumothorax or pneumomediastinum is confirmed by chest X ray or CT

mechanical ventilation free daysday 28

days without mechanical ventilation during ICU

hospital mortalityDay 90 (censored at hospital discharge if discharge prior to Day 90)

mortality at hospital discharge

hospital length of stayDay 90

hospital length of stay at hospital discharge

occurrence of SMZ/TMP treatment failureday 7 after SMZ/TMP treatment

SMZ/TMP treatment failure is defined as worsening P/F or radiographic features with a requirement for an increased respiratory support after 7 days of SMZ/TMP treatment (SMZ/TMP)

occurrence of non-invasive mechanical ventilationday 28

Non-invasive mechanical ventilation failure is defined as need for switch from non-invasive mechanical ventilation to invasive mechanical ventilation due to deteriorated respiratory failure

ICU acquired infectious diseaseday 28

incidence of pulmonary of extra-pulmonary infections. Diagnosis of infections disease will be defined by the need of treatment.

© Copyright 2025. All Rights Reserved by MedPath